首页 | 本学科首页   官方微博 | 高级检索  
     

血浆纤溶酶原激活物抑制物1及血清转化生长因子β与2型糖尿病肾病的相关性研究
引用本文:徐丰博,刘惠兰,孙懿. 血浆纤溶酶原激活物抑制物1及血清转化生长因子β与2型糖尿病肾病的相关性研究[J]. 临床荟萃, 2012, 27(3): 210-212,216
作者姓名:徐丰博  刘惠兰  孙懿
作者单位:首都医科大学附属复兴医院肾内科,北京,100038
摘    要:目的 研究2型糖尿病肾病(DN)及单纯2型糖尿病(T2DM)患者血浆纤溶酶原激活物抑制物1(PAI-1)及血清转化生长因子β(TGF-β)水平的变化.并进一步探讨在T2DM患者中血浆PAI-1和血清TGF-β的关系.方法 T2DM患者93例,其中T2DM无蛋白尿患者(DM组)37例;微量蛋白尿患者(DN 1组)27例,尿白蛋白/肌酐(A/C)20~200 mg/g;显著蛋白尿患者(DN 2组)29例,A/C>200 mg/g.选取正常对照组32例,均为健康体检者.所有检测对象过夜禁食10~12小时后,于清晨空腹抽取肘静脉血4 ml,其中2 ml不抗凝血用于生化指标检测.酶联免疫吸附试验(ELISA)测定血浆PAI-1、TGF-β水平.结果 ①血浆PAI-1水平DN1、DN2组显著高于正常对照组,(69.28±18.61) ng/L、(69.43±17.86) ng/L vs (51.97±30.11) ng/L(P<0.05).②血清TGF-β水平DM、DN1、DN2组显著高于正常对照组,分别为(137.99±21.47) ng/L、(180.36±40.45) ng/L、(298.92±77.37) ng/L vs(100.65±24.21) ng/L(均P<0.01).③血清TGF-β和血浆PAI-1水平无明显相关性.④血浆PAI-1水平及血清TGF-β水平升高是T2DM并发肾病的危险因素.结论 T2DM合并肾病患者血浆PAI-1水平、血清TGF-β水平升高,两项指标可以预测T2DM合并肾病的危险.

关 键 词:胰腺炎  

Correlation of plasminogen activator inhibitor-1 and transforming growth factor-beta with diabetic nephropathy in type 2 diabetes mellitus
XU Feng-bo , LIU Hui-lan , SUN Yi. Correlation of plasminogen activator inhibitor-1 and transforming growth factor-beta with diabetic nephropathy in type 2 diabetes mellitus[J]. Clinical Focus, 2012, 27(3): 210-212,216
Authors:XU Feng-bo    LIU Hui-lan    SUN Yi
Affiliation:Department of Nephrology,Fu Xing Hospital,Capital Medical University,Beijing 100038,China
Abstract:Objective Plasma plasminogen activator inhibitor-1(PAI-1) and transforming growth factor-beta(TGF-β) level of type 2 diabetes patients were studied for exploring the pathophysiological mechanism.Methods According to the standards of diabetic diagnosis and typing put forward by ADA in 1997,a total of 93 unrelated patients with type 2 diabetes were randomly recruited in the study.These patients were further divided into type 2 diabetes with nephropathy(DN1、DN2) and without nephropathy(DN) according to their urinary albumin to creatinine ratio(A/C).At the same time,32 healthy controls were selected from population for regular physical examination in the hospital.The levels of PAI-1 and TGF-β were measured by enzyme-linked immunosorbent assay(ELISA).Results ①The plasma PAI-1 levels in DN1 and DN2 group were higher than that in healthy controls,(69.28±18.61) ng/L,(69.43±17.86) ng/L vs(51.97±30.11) ng/L(P0.05).② The levels of TGF-β in DM,DN1 and DN2 group were higher than that in healthy controls,(137.99±21.47) ng/L,(180.6±40.45) ng/L,(298.92±77.37) ng/L vs(100.65±24.21) ng/L(all P0.01).③The level of plasma PAI-1 was not related to the level of TGF-β.④The higher level of PAI-1 and TGF-β were risk factors of type 2 diabetes nephropathy.Conclusion In type 2 diabetes or complicated nephropathy patients,the levels of PAI-1 and TGF-β are higher,both items can predict type 2 diabetes nephropathy.
Keywords:diabetic nephropathy  plasminogen activator inhibitor 1  transforming growth factor beta
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《临床荟萃》浏览原始摘要信息
点击此处可从《临床荟萃》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号